Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.Journal of global oncology · 2019
   Observational
2. Goals, globalization and the impact factor of the journal.Revista brasileira de hematologia e hemoterapia · 2014
   Article
3. The Guidelines Project: Brazilian guidelines for acute promyelocytic leukemia.Revista brasileira de hematologia e hemoterapia · 2014
   Article
4. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I.Hematology, transfusion and cell therapy
   Article
5. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.Revista brasileira de hematologia e hemoterapia
   Article
6. Five years of implementation of guidelines in hematology and transfusion medicine in Brazil.Revista brasileira de hematologia e hemoterapia
   Article
7. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Revista brasileira de hematologia e hemoterapia
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.